Tackling Biological Risk in the Workplace: Updates and Prospects Regarding Vaccinations for Subjects at Risk of Occupational Exposure in Italy.
occupational biological risk
occupational medicine
preventive and protective measures
vaccinations
workplace
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
08 Oct 2019
08 Oct 2019
Historique:
received:
20
09
2019
accepted:
23
09
2019
entrez:
11
10
2019
pubmed:
11
10
2019
medline:
11
10
2019
Statut:
epublish
Résumé
Occupational activities may expose workers to a variety of risks. Exposure to biological agents constitutes a traditional risk in numerous occupational settings. Legislative Decree (D.Lgs.) 81/2008 constitutes the main Italian legislative basis for the management and the prevention of biological risk in occupational settings and lists the available vaccinations against each single biological agent. The 2017-2019 National Vaccination Prevention Plan (PNPV) identifies some categories of workers for whom specific vaccinations are indicated. In this context, the occupational physician identifies work processes that are at risk-identifying susceptible workers and providing information on health monitoring-and is responsible for ensuring that vaccinations are carried out. Adequate and thorough evaluation of risk are indispensable to appropriate consultation by the occupational physician in order to enable the employer to provide efficacious vaccinations. Close collaboration among the services of occupational medicine, vaccination clinics, and healthcare management together with the implementation of vaccination programs that are agreed upon at the institutional level provides an opportunity to reduce the number of workers who are susceptible to vaccine-preventable diseases, thereby yielding benefits in terms of biological risk management in the workplace and contributing to increasing vaccination coverage rates, which in many cases are currently unsatisfactory.
Identifiants
pubmed: 31597371
pii: vaccines7040141
doi: 10.3390/vaccines7040141
pmc: PMC6963441
pii:
doi:
Types de publication
Editorial
Langues
eng
Déclaration de conflit d'intérêts
P. Durando received funds for sponsorized clinical trials and get involved in Advisory boards from GSK, Novartis, Pfizer and Sanofi Pasteur in the last 5 years.
Références
Ind Health. 2012;50(4):326-37
pubmed: 22785422
Euro Surveill. 2017 Sep 14;22(37):
pubmed: 28933342
J Prev Med Hyg. 2018 Mar 30;59(1):E8-E13
pubmed: 29938234
J Prev Med Hyg. 2019 Mar 29;60(1):E12-E17
pubmed: 31041405